Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

Shree Ganesh Biotech (India) L

Healthcare › Pharmaceuticals & Biotechnology
₹0.46
at close · 28 Oct 2026
▲ 0.00 (+0.00%)

Latest filings

Next results: Mon, 2 Nov · Financial Results
  1. Board meeting to approve second-quarter and half-year results · Results
  2. Reg 74(5) Compliance Certificate Filing for Q2 FY27 · Compliance
  3. AGM voting results: both resolutions passed · Board & Shareholder Meetings
All filings ↓
Ask Nexa about Shree Ganesh Biotech (India) L

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹5 Cr over the trailing twelve months.

Market Cap
₹18 Cr
P / E (TTM)
23.0×
EV / EBITDA
35.6×
Div Yield
—
Growth
-22.0%▼
Revenue 5y CAGR
PAT +3.6% · EBITDA +3.7%
Quality
1.4%·
ROCE (5y median)
ROE 1.0% (5y median) · margin 10.4%
Leverage
0.00·
Debt / Equity · low
Net cash ₹0.01 Cr
Revenue FY21→FY26
0.3×▼
Margin +5.8 pts
₹17 Cr → ₹5 Cr
Cash conversion
-1.83×▼
Operating cash ÷ profit · 5 yrs
₹-11 Cr on ₹6 Cr
Moves on a normal day
1.59%·
Median daily move
Last 268 sessions · the yardstick for filing-day moves
Where it sits among 191 Pharmaceuticals & Biotechnology peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#62/164
P/B#4/169
ROCE#154/189
ROE#142/172
Debt / Equity#1/172
EBITDA margin#163/170
Revenue growth#151/166
Profit growth#41/164

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals & Biotechnology peers · as of FY26 — not investment advice

Strengths
No borrowings on the balance sheet
lower than 78% of its 172 Pharmaceuticals & Biotechnology peers
Concerns
Revenue shrinking over 5 years (−22% a year)
Erratic profits — up in only 2 of the last 5 years
Returns on capital 1.4% (5-year median)
#154 of 189 in Pharmaceuticals & Biotechnology on the latest reported figures
Over 5 years it reported ₹5.84 Cr of profit and an operating cash outflow of ₹11 Cr — -1.83×
Less than 60p of every ₹1 of profit arrived as cash
Heavy working capital — 861 days of cash tied up
EPS grew slower than profit — the share count rose (bonus or dilution)

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from Shree Ganesh Biotech (India) L's filed financials and exchange disclosures

What does Shree Ganesh Biotech (India) L do?

Shree Ganesh Biotech (India) L is a Pharmaceuticals & Biotechnology company listed on BSE.

Is Shree Ganesh Biotech (India) L profitable?

Yes. Over the trailing twelve months Shree Ganesh Biotech (India) L reported a net profit of ₹0.51 Cr on revenue of ₹4.97 Cr.

Does Shree Ganesh Biotech (India) L pay a dividend?

Not in the latest reported year — Shree Ganesh Biotech (India) L's dividend payout for FY26 was nil.

Is Shree Ganesh Biotech (India) L debt-free?

Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹0.01 Cr of cash.

Is Shree Ganesh Biotech (India) L expensive compared with its peers?

On trailing P/E, Shree Ganesh Biotech (India) L ranks 62 of 164 in Pharmaceuticals & Biotechnology — cheaper than 63% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.

How much does the Shree Ganesh Biotech (India) L share price move in a day?

On a typical session Shree Ganesh Biotech (India) L moves 1.59% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.

When are Shree Ganesh Biotech (India) L's next results?

Financial Results on Mon, 2 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.

Where can I track Shree Ganesh Biotech (India) L's announcements?

Every NSE and BSE filing by Shree Ganesh Biotech (India) L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.